IBT was established in 1994 to provide institutional and retail investors with the opportunity to participate in global biotechnology and life science companies, from venture-stage development via venture capital (SV Health Investors) funds through to global, multinational biotechnology companies. The main aim of the trust is to generate capital growth, while minimising risk, through a diversified portfolio and an experienced investment team. Over the last five years, IBT’s NAV per share has increased 25%, while the share price has increased 32% over the same period – the superior returns generally reflected by a reduction in the share price discount.
30 Jun 2022
International Biotechnology Trust (IBT) - M&A activity on the rise
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
International Biotechnology Trust (IBT) - M&A activity on the rise
International Biotechnology Trust PLC (IBT:LON) | 610 -12.2 (-0.3%) | Mkt Cap: 230.8m
- Published:
30 Jun 2022 -
Author:
Martin Hall -
Pages:
22
IBT was established in 1994 to provide institutional and retail investors with the opportunity to participate in global biotechnology and life science companies, from venture-stage development via venture capital (SV Health Investors) funds through to global, multinational biotechnology companies. The main aim of the trust is to generate capital growth, while minimising risk, through a diversified portfolio and an experienced investment team. Over the last five years, IBT’s NAV per share has increased 25%, while the share price has increased 32% over the same period – the superior returns generally reflected by a reduction in the share price discount.